Abbott Laboratories research snapshot
ABT AI stock analysis currently reads Abbott Laboratories as a diversified healthcare company whose medical devices, diagnostics, nutrition, and established pharmaceuticals franchises are building momentum after a strong second quarter. At the August 2, 2026 data cutoff, ABT traded near $105.70, about 10% above the prior month, with a verified market capitalization near $182.90 billion after Abbott raised its full-year 2026 adjusted EPS guidance. The analysis uses scenario ranges and source checks, not a certain price prediction, and is for informational use only.
Current price
$105.70
Market cap
$182.90 billion
AI score
70 / 100
Rating
Diversified healthcare compounder, improving momentum
Trend status
Recovery above short-term averages, 200-day test ahead
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Abbott sells essential healthcare products across Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals, with Q2 2026 comparable sales growth of 4.8% and full-year guidance for 6.5% to 7.5% comparable growth. | High |
| Moat | Moat comes from regulated products, clinical data, installed systems, global distribution, manufacturing scale, product brands, and switching costs in devices and diagnostics. | Medium-high |
| Management | Management delivered a Q2 beat, raised 2026 adjusted EPS guidance, and reaffirmed comparable sales guidance. Capital allocation should still be judged by Exact Sciences integration, debt reduction, and R&D productivity. | Medium |
| Financial trend | FY2025 sales grew 5.7% to $44.328 billion, while Q2 2026 reported sales grew 13.0% with adjusted EPS of $1.31, above the $1.28 consensus. | High |
| Valuation | Using the $5.525 midpoint of the raised 2026 adjusted EPS guidance, the stock traded near 19.1x forward adjusted EPS, about 3.6x book, and near 24.8x TTM free cash flow per share. | Medium-high |
| Technical trend | ABT holds above the 50-day moving average near $93 and the 100-day near $95, but the 200-day moving average near $108 is the next trend test. | Medium |
| Risk level | Key risks include Exact Sciences integration and debt, Nutrition volume recovery, Diagnostics growth concentration, reimbursement pressure, product quality issues, cyber events, currency, and medtech competition. | Medium-high |
| AI confidence | High for descriptive facts and audited math. Lower for forecast ranges because healthcare multiples and product growth can reprice fast after earnings or regulatory news. | High data confidence |
| Investment certainty | Medium certainty. The page gives a research framework and scenario ranges, not a buy or sell instruction. | Medium |
ABT AI stock forecast
The ABT AI stock forecast uses scenario math around the $105.70 quote and Abbott raised 2026 adjusted EPS guidance of $5.45 to $5.60. Using the $5.525 midpoint of adjusted EPS guidance, the audited three-year framework produced a bearish area near $91, a base area near $129, and a bullish area near $162 before dividends.
$150 to $165
More likely if Medical Devices keeps high single-digit to low double-digit growth, Libre and electrophysiology stay strong, Nutrition returns to positive growth, Exact Sciences adds durable Cancer Diagnostics revenue, and leverage falls without cutting R&D intensity.
$120 to $135
More likely if Abbott compounds adjusted EPS in the mid single digits, maintains strong free cash flow conversion, and the market keeps an earnings multiple near the current level.
$85 to $95
More likely if acquisition debt constrains capital returns, Nutrition stays weak, Diagnostics growth depends too heavily on Exact Sciences, Libre competition intensifies, or investors assign a lower multiple to slower healthcare growth.
ABT AI technical analysis
ABT AI technical analysis is constructive as of the August 2, 2026 data cutoff. The stock closed near $105.70, above the 50-day moving average near $93 and the 100-day near $95, with the 200-day moving average near $108 as the next key trend test. RSI near 67 is firm but not yet overbought.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $105.70 | StockAnalysis and Yahoo Finance quote snapshots showed a July 31, 2026 close near this level. |
| Near support | $99.08 | Barchart placed the 20-day moving average near this level, the first support below the current quote. |
| Moving average support | $93.30 to $95.34 | The 50-day and 100-day moving averages sit in this zone, marking the key recovery support cluster. |
| Deeper support | $81.97 | StockAnalysis listed this as the 52-week low. A retest would signal a failed recovery. |
| Near resistance | $108.35 | The 200-day moving average sits near this level. A weekly close above it would strengthen the long-term trend. |
| Upper resistance | $137.49 | The 52-week high remains a distant ceiling within the current trading range. |
| Momentum | RSI roughly 67 | StockAnalysis and Barchart showed RSI readings near 67, firm momentum that is not yet overbought. |
| Volume | Average volume near 12.5 million shares | The 20-day average volume sits near 12.5 million shares, useful for judging breakout quality. |
| Volatility | ATR near $3.10 (about 2.9%) | Barchart showed a 14-day ATR near $3.10, with the 52-week range still wide from $81.97 to $137.49. |
| Invalidation | Close below $93 | A decisive close below the 50-day moving average cluster would weaken the recovery setup. |
ABT AI trading strategy
The ABT AI trading strategy is a rules-based research framework for monitoring a healthcare quality stock after a Q2 earnings beat and guidance raise. It is not personal advice and should be paired with fresh chart data, filings, position sizing, and a defined invalidation level.
Watch for ABT to hold above the $99 20-day moving average, then reclaim and hold the $108 200-day area on volume above average. A sustained move above $108 would be the bigger long-term trend check.
A close below $93 or a failed test of the $108 area after the next earnings update should invalidate the near-term recovery setup.
If ABT pulls back toward the $99 to $101 support zone without fresh balance sheet or guidance damage, compare the price reaction with Q3 results, Libre growth, Nutrition volume data, and Exact Sciences integration costs.
Do not average down without a maximum loss rule because healthcare stocks can gap on product, legal, regulatory, reimbursement, or cyber news.
Track comparable sales growth, adjusted EPS guidance, free cash flow, Exact Sciences integration costs, total debt, Libre growth, Medical Devices margins, and Nutrition volume recovery.
Reduce confidence if EPS growth depends mainly on adjustments or financial leverage instead of organic demand and cash generation.
Investment research summary
Abbott turns regulated healthcare science, device engineering, diagnostics platforms, nutrition brands, and emerging market pharmaceuticals into recurring demand from patients, clinicians, labs, and caregivers.
The moat is portfolio-based. Clinical validation, regulatory approvals, device training, channel access, manufacturing scale, and trusted brands make fast replication difficult, though no single line is immune from competition.
The thesis fails if debt from Exact Sciences limits flexibility, Libre growth slows faster than expected, Nutrition does not recover, Diagnostics growth depends too much on acquisition, or pricing and reimbursement pressure compress margins.
Management should be measured by portfolio discipline, integration execution, R&D return, debt reduction, dividend coverage, and willingness to protect long-term product investment over short-term EPS optics.
Abbott sits inside long-duration healthcare demand from aging populations, chronic disease, diabetes monitoring, cancer diagnostics, and global access to branded generic medicines.
At about 19.1x raised 2026 adjusted EPS guidance, valuation is higher than the start of July after the Q2 re-rating. Margin of safety depends on restoring Nutrition growth and proving Exact Sciences integration while absorbing acquisition debt.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ABT price | $105.70 | StockAnalysis quote snapshot | July 31, 2026 |
| Market capitalization | $182.90 billion, verified as $105.70 x 1.73 billion shares | financial_rigor.py market cap verification | August 2, 2026 |
| Q2 2026 sales and adjusted EPS | $12.593 billion sales, 13.0% reported growth, 4.8% comparable growth, $1.31 adjusted diluted EPS | Abbott Q2 2026 results release | August 2, 2026 |
| 2026 adjusted EPS guidance | $5.45 to $5.60, raised from $5.38 to $5.58 | Abbott Q2 2026 results release | August 2, 2026 |
| FY2025 revenue | $44.328 billion, cross-checked against third-party $44.33 billion figures | Abbott FY2025 results release and Macrotrends cross-check | August 2, 2026 |
| FY2025 net income | $6.524 billion | Macrotrends net income data | August 2, 2026 |
| FY2025 free cash flow | $7.395 billion | Macrotrends free cash flow data | August 2, 2026 |
| Cash and total debt | $5.60 billion cash and $32.72 billion total debt | StockAnalysis statistics and balance sheet cross-check | August 2, 2026 |
| Valuation check | 19.13x forward adjusted EPS on guidance midpoint, 3.58x book, 24.81x TTM free cash flow per share, 2.38% dividend yield | financial_rigor.py valuation verification | August 2, 2026 |
| Technical snapshot | 20-day SMA near $99.08, 50-day SMA near $93.30, 100-day SMA near $95.34, 200-day SMA near $108.35, RSI near 66.8 | Barchart and StockAnalysis technical snapshots | August 2, 2026 |
This ABT AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, product news, acquisition updates, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
